Dyne Therapeutics To Submit BLA To FDA For Z- Rostudirsen

Dyne Therapeutics has advanced Z-rostudirsen toward FDA approval by filing a Biologics License Application for Duchenne muscular dystrophy amenable to exon 51 skipping. The company is seeking priority review for Z-rostudirsen (Zeleciment rostudirsen, or DYNE-251), an investigational therapy. In the Phase 1/2 DELIVER trial, the drug met its primary endpoint, and data from the registrational expansion cohort showed a statistically significant increase in dystrophin production with functional improvements across multiple endpoints and a favorable safety profile. The proposed dose regimen is 20 mg/kg IV every four weeks, and Dyne is continuing the long-term extension and global FORZETTO Phase 3 study.

Dyne indicated a potential U.S. launch in the first quarter of 2027 if approved. The FDA has granted Fast Track and Rare Pediatric Disease designations for Z-rostudirsen, while the EMA and Japan’s MHLW have awarded orphan drug status. Beyond Z-rostudirsen, the company is advancing four additional candidates—DYNE-253, DYNE-245, DYNE-244, and DYNE-255—for exon-skipping in other DMD mutations. Market research places the global Duchenne drugs market at about $3.47 billion in 2023 and projected to reach $9.91 billion by 2030, underscoring growth potential and the competitive landscape. DYN closed Tuesday's trading at $18.15, up 4.49%, with overnight trading at $18.33.